Here, we report primary efficacy and safety data from an independent analysis in Chinese patients in IMpower132 evaluating atezolizumab plus pemetrexed and cisplatin for first‐line treatment of non‐squamous EGFR‐ or ALK‐negative NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.